Fecal microbiota transplantation is gaining attention as a novel treatment for various diseases, including digestive disorders such as ulcerative colitis.
By balancing the gut flora*, improvement in symptoms can be expected.
(A collection of gut bacteria, or the microbial community containing them)
Research indicates that fecal microbiota transplantation can alleviate symptoms and promote recovery in patients with refractory ulcerative colitis. Furthermore, fecal microbiota transplantation can be used in combination with conventional treatments, reportedly yielding better outcomes.
Fecal microbiota transplantation
Fecal microbiota transplantation is a treatment in which stool collected from a healthy donor is purified to remove impurities and then transplanted into the patient’s intestines.
This method is primarily performed to restore the balance of the intestinal flora.
When gut flora becomes disrupted, symptoms of digestive disorders may worsen. However, fecal transplantation—which involves transferring the entire healthy ecosystem of a donor’s gut bacteria—is expected to restore health.
In the 2000s, C. difficile colitis (CDI) became a serious societal problem in Europe and the United States, drawing attention to the effectiveness of FMT.
Additionally, fecal microbiota transplantation is said to be effective, particularly for patients with intractable diseases such as ulcerative colitis and Crohn’s disease. Clinical studies indicate that many patients who undergo fecal microbiota transplantation experience symptom improvement, and some patients even achieve remission.
However, fecal transplantation must be performed under strict medical supervision.
The selection of donors and testing of collected stool samples are essential, and ensuring safety is crucial.
Effect of fecal transplant
Fecal microbiota transplantation is a treatment aimed at normalizing the balance of microorganisms in the gut.
It is particularly expected to improve symptoms in patients with ulcerative colitis and Crohn’s disease.
Disruption of the gut flora is thought to be involved in the onset and worsening of these diseases.
Many patients who have undergone fecal microbiota transplantation report experiencing relief from symptoms such as abdominal pain, diarrhea, and constipation. Additionally, cases have been observed where intestinal inflammation decreases and the disease condition stabilizes.
This occurs because beneficial microorganisms in the transplanted stool proliferate within the patient’s intestines and exert an anti-inflammatory effect.
However, the effectiveness of fecal transplantation varies significantly between individuals and is not guaranteed to work for all patients. Choosing this treatment method requires thorough consultation with healthcare professionals and appropriate diagnosis.
Modulation of the Gut Microbiota
The gut microbiota is a crucial factor significantly impacting our health.
Particularly in digestive disorders like ulcerative colitis and Crohn’s disease, an imbalance in the gut’s microbial balance is a contributing factor to inflammation, leading to various symptoms.
Fecal microbiota transplantation (FMT) is gaining attention as a means to adjust the gut microbiota.
The goal is to replenish beneficial microorganisms in the gut and restore balance by transplanting stool from a healthy donor. By improving the intestinal environment through this therapy, inflammation can be suppressed, and symptom improvement is anticipated.
However, since adjustments to the gut microbiota vary greatly between individuals, dramatic effects do not occur in all patients.
Improving the intestinal environment often takes time, making collaboration with healthcare professionals essential.
Selecting treatment methods tailored to each patient’s individual condition is key to achieving better outcomes.
Effect on Ulcerative Colitis
The efficacy of fecal microbiota transplantation for ulcerative colitis has been demonstrated in numerous studies.
A primary effect is the restoration of gut microbiota diversity.
Since ulcerative colitis involves a reduction in beneficial bacteria, an imbalanced increase in certain gut bacteria, and decreased gut microbial diversity, introducing new bacteria (more broadly, the entire microbiome) from a healthy donor leads to symptom improvement.
Specifically, many patients who received fecal transplants experienced significant reductions in the frequency of abdominal pain and diarrhea, and many were relieved from chronic constipation.
Furthermore, based on data from medical institutions, some patients showed decreased inflammation markers and achieved good control of inflammation.
However, the effectiveness of fecal transplants can vary depending on each patient’s gut environment and treatment history. Therefore, it is important to consult with your doctor to choose the treatment method that is right for you.
Application to Other Diseases
Fecal microbiota transplantation extends beyond treating ulcerative colitis, with applications expanding to other diseases.
Recent research is increasingly revealing links between gut microbiota and various illnesses.
For instance, fecal transplants are being attempted for conditions like diarrhea-predominant irritable bowel syndrome and antibiotic-associated diarrhea. Since imbalances in the gut microbiome influence these disorders, introducing beneficial microbes through transplantation is expected to improve symptoms.
Furthermore, the influence of the gut environment has been noted in metabolic disorders like obesity and diabetes. Improving the gut flora through fecal transplantation may contribute to weight management and metabolic improvement.
However, these applications to other diseases are still in the research phase, and evidence is not yet established. Therefore, careful judgment is required. It is crucial to proceed after thorough consultation with healthcare professionals to deepen understanding.
Fecal Transplant Method
The process of fecal transplantation begins with selecting a healthy donor.
The donor undergoes thorough screening to confirm the absence of infectious diseases or gastrointestinal disorders. This ensures the safety of the fecal material.
Next, the collected fecal matter from the donor is prepared. Typically, the stool is mixed with a solvent such as saline solution and impurities are removed to achieve a smooth consistency. Following this preparation, the procedure for transplanting the stool into the patient is performed.
Methods for fecal transplantation include directly injecting stool into the intestine using an endoscope or ingesting stool orally via a capsule.
After fecal transplantation, the patient is observed for several days to weeks until the intestinal environment recovers, and the effectiveness is confirmed. The key point here is to carefully manage the patient’s physical condition following the transplant.
Treatment Process
The fecal microbiota transplantation treatment process involves several stages. First, patients interested in the treatment visit a specialized medical facility. Through consultation with a physician, the patient’s symptoms and medical history are thoroughly reviewed to determine if fecal microbiota transplantation is appropriate.
Next, the patient undergoes an intestinal flora balance test. Based on the results confirming the patient’s intestinal flora balance status, the optimal bacterial solution is prepared.
Then, a healthy donor is selected. The donor undergoes rigorous screening to ensure they pose no risk of infectious diseases or gastrointestinal disorders. Once an acceptable donor is confirmed, the process moves to the collection and preparation of stool.
Following this, the transplant is performed. The stool is transplanted into the patient’s intestines using endoscopy or a capsule.
After treatment, the patient’s progress is monitored, and changes in symptoms and improvements in the intestinal environment are evaluated.
Additional support and follow-up are provided as needed, and it is crucial to carefully manage the patient’s condition.
Then, a healthy donor is selected. The donor undergoes rigorous screening to ensure they pose no risk of infectious diseases or gastrointestinal disorders. Once an acceptable donor is confirmed, the process moves to the collection and preparation of stool.
Following this, the transplant is performed. The stool is transplanted into the patient’s intestines using endoscopy or a capsule.
After treatment, the patient’s progress is monitored, and changes in symptoms and improvements in the intestinal environment are evaluated.
Additional support and follow-up are provided as needed, and it is crucial to carefully manage the patient’s condition.
Selecting a donor is critically important in fecal microbiota transplantation.
First, the donor must be healthy. This requires detailed screening to confirm the absence of infectious diseases and digestive system disorders.
Particular attention must be paid to investigating any history of hepatitis, HIV, or intestinal infections.
Additionally, the donor’s diet and lifestyle habits are considered.
Individuals who maintain a diet rich in nutrients essential for healthy gut flora are preferred.
Furthermore, avoiding smoking and excessive alcohol consumption are also desirable conditions for donors.
By considering these points, safe and effective fecal microbiota transplantation can be performed.
Cost of fecal transplant
The cost of fecal microbiota transplantation varies by facility and region, making it difficult to provide a specific figure. However, since fecal microbiota transplantation is currently an out-of-pocket treatment not covered by insurance, it generally ranges from several hundred thousand yen to around one million yen. The final number of transplant sessions also depends on the patient’s symptoms.
When considering fecal microbiota transplantation, it is important to confirm in advance how much the out-of-pocket expense will be. Consulting with a medical institution and obtaining a detailed estimate will allow you to approach treatment with greater peace of mind.
General Cost Estimates
When considering general cost estimates, the choice of fecal transplant method affects the total expense.
For example, when using the donor bank operated by the General Incorporated Foundation Clinical Research Association for Fecal Microbiota Transplantation (https://fmt-japan.org/technical-features/japanbiome), the cost of the transplant consists of the medical institution’s consultation fee, intestinal flora testing fee, and the transplant fee itself. The donor bank usage fee is included in the transplant cost. The procedure, performed using a medical rubber tube, takes only a few tens of minutes, so hospitalization is not required. Neither antibiotic administration nor dietary restrictions are necessary.
On the other hand, for fecal transplants performed at other facilities or institutions not using a donor bank, the costs associated with the procedure include medical consultation fees, testing costs, and hospitalization expenses related to the treatment. Specifically, preparatory procedures and follow-up consultations are often required, which can increase the overall cost.
Additionally, regarding stool provision, when not using a donor bank, selecting a donor and conducting tests to assess their health status is necessary. Therefore, costs related to the donor are generally incurred separately.
As such, the final cost varies depending on the policies of the medical institution providing treatment and the local healthcare environment. Therefore, obtaining a detailed estimate in advance is advisable.
Insurance Coverage Eligibility
Coverage for fecal microbiota transplantation varies by country and region.
In Japan, fecal microbiota transplantation is not covered by insurance and is currently 100% out-of-pocket.
Risks and Precautions of Fecal Transplantation
Side Effects and Risks
While fecal transplantation holds promise for effectiveness, it also carries side effects and risks.
First, as a common side effect, diarrhea and abdominal pain may occur after transplantation.
These symptoms are caused by a sudden change in the gut flora.
These symptoms are usually temporary and improve as the body adapts to the new intestinal environment. However, if they become unbearable, it is important to consult a healthcare provider.
Furthermore, a major concern regarding the risks of fecal transplantation is the potential for infection.
In particular, if the transplanted stool from the donor contains pathogens, there is a risk of causing infection.
Therefore, donor selection and rigorous screening are essential.
Additionally, beyond the fecal transplant method requiring the patient to find a donor within the second degree of kinship themselves, there is also the option of utilizing the aforementioned donor bank (Japanbiome, Japan’s first fecal bank).
Japanbiome implements strict donor management and has established an ethics committee.
The choice of which transplant to undergo should be made through thorough consultation with medical professionals, taking into account individual circumstances.
Characteristics of patients requiring attention
When considering fecal microbiota transplantation, certain patient characteristics warrant particular caution.
First, patients taking immunosuppressive drugs. These medications increase the risk of infection, necessitating careful judgment before performing transplantation.
Next, patients with anatomical abnormalities of the intestine also require caution.
This includes a history of previous surgery or congenital intestinal disorders. Such patients may be less likely to benefit from the treatment.
Furthermore, mental health status should also be considered.
Patients with psychological issues may lack sufficient understanding or patience regarding the treatment.
By being aware of these characteristics, healthcare providers can formulate an appropriate treatment plan.
Latest Research and Future Prospects
Recent research findings
Recent research findings indicate increasing evidence that fecal microbiota transplantation contributes to symptom relief in ulcerative colitis.
Additionally, clinical trials have reported that approximately 50% of patients who received fecal transplants experienced symptom improvement. This finding offers promising news for patients with refractory conditions who have not responded to conventional treatments.
Regarding cancer treatment, fecal microbiota transplantation is gaining attention for its potential to enhance the efficacy of immunotherapy. It is expected to improve the gut environment and strengthen immune responses, with ongoing research exploring its safety and effectiveness as a treatment modality.
Furthermore, successful cases have been reported in multiple clinical trials, increasing the likelihood that fecal microbiota transplantation will be positioned as part of standard treatment. In August 2024, a clinical trial of fecal microbiota transplantation began for patients with esophageal and gastric cancer.
Additionally, recent data suggests the potential for reduced cancer recurrence rates after fecal microbiota transplantation, raising expectations for long-term effects as well.
However, since fecal microbiota transplantation is still a new treatment, there is insufficient data on its safety and long-term efficacy. It is hoped that in the future, these challenges will be resolved, leading to the development of a treatment that can be safely offered to more patients.
Summary
Fecal microbiota transplantation is gaining attention as a novel treatment approach for gastrointestinal diseases, including ulcerative colitis.
By improving the gut environment, it holds potential for alleviating symptoms. Numerous studies are underway, and practical applications are increasing.
However, caution is required with fecal microbiota transplantation. Essential processes for ensuring safety, such as donor selection and infection risk management, are indispensable. Collaboration with healthcare professionals is also crucial, and deepening appropriate understanding of the treatment is necessary.
As research progresses on the efficacy and indications for fecal microbiota transplantation, it is expected to broaden treatment options for patients. While development of new drugs and therapies targeting the gut microbiota continues, fecal microbiota transplantation is likely to strengthen its position as a foundational approach.
Individuals suffering from ulcerative colitis and their families are encouraged to consider consulting a medical institution.
References
1. Allegretti, J. R., Mullish, B. H., Kelly, C., & Fischer, M. (2019).
The evolution of the use of fecal microbiota transplantation and emerging therapeutic indications.
The Lancet, 394(10196), 420–431.
2. Bennet, J. D., & Brinkman, M. (1989).
Treatment of ulcerative colitis by implantation of normal colonic flora.
The Lancet, 1(8630), 164.
3. Cammarota, G., Ianiro, G., Tilg, H., Rajilić–Stojanović, M., Kump, P., Satokari, R., … & Gasbarrini, A. (2017).
European consensus conference on faecal microbiota transplantation in clinical practice.
Gut, 66(4), 569–580.
4. Costello, S. P., Hughes, P. A., Waters, O., Bryant, R. V., Vincent, A. D., Blatchford, P., … & Andrews, J. M. (2019).
Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: A randomized clinical trial.
JAMA, 321(2), 156–164.
5. Lopetuso, L. R., Ianiro, G., Allegretti, J. R., Bibbò, S., Gasbarrini, A., Scaldaferri, F., & others. (2020).
Fecal transplantation for ulcerative colitis: Current evidence and future applications.
Expert Opinion on Biological Therapy, 20(5), 343–351.
6. Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., … & Marshall, J. K. (2015).
Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial.
Gastroenterology, 149(1), 102–109.e6.
7. Mullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., … & Williams, H. R. T. (2018).
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.
Gut, 67(11), 1920–1941.
8. Ooijevaar, R. E., Terveer, E. M., Verspaget, H. W., Kuijper, E. J., & Keller, J. J. (2019).
Clinical application and potential of fecal microbiota transplantation.
Annual Review of Medicine, 70, 335–351.
9. Paramsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., … & Borody, T. J. (2017).
Multidonor intensive fecal microbiota transplantation for active ulcerative colitis: A randomized placebo-controlled trial.
The Lancet, 389(10075), 1218–1228.
10. Rossen, N. G., MacDonald, J. K., de Vries, E. M., D’Haens, G. R., de Vos, W. M., Zoetendal, E. G., & Ponsioen, C. Y. (2015).
Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review.
World Journal of Gastroenterology, 21(17), 5359–5371.
Supervisor: Dr. Hideaki Shima, Ph.D. in Agriculture (Symbiotics Co., Ltd.)
